Remission of photosensitivity following treatment of psoriasis vulgaris with tumour necrosis factor inhibitors.
Viguier
M
M
Jeanmougin
M
M
Begon
E
E
Verola
O
O
Dubertret
L
L
Bachelez
H
H
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D010787:Photosensitivity Disorders / Q000517:prevention & control*; D011565:Psoriasis / Q000150:complications* / Q000209:etiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept